- Home
- GILD vs ANET Comparison
GILD vs ANET Comparison
Compare GILD & ANET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- ANET
- Stock Information
- Founded
- GILD 1987
- ANET 2004
- Country
- GILD United States
- ANET United States
- Employees
- GILD N/A
- ANET N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- ANET Computer Communications Equipment
- Sector
- GILD Health Care
- ANET Telecommunications
- Exchange
- GILD Nasdaq
- ANET Nasdaq
- Market Cap
- GILD 113.0B
- ANET 127.4B
- IPO Year
- GILD 1992
- ANET 2014
- Fundamental
- Price
- GILD $92.98
- ANET $114.24
- Analyst Decision
- GILD Buy
- ANET Buy
- Analyst Count
- GILD 26
- ANET 20
- Target Price
- GILD $96.71
- ANET $98.11
- AVG Volume (30 Days)
- GILD 6.4M
- ANET 7.1M
- Earning Date
- GILD 02-11-2025
- ANET 02-10-2025
- Dividend Yield
- GILD 3.38%
- ANET N/A
- EPS Growth
- GILD N/A
- ANET 38.55
- EPS
- GILD 0.10
- ANET 2.08
- Revenue
- GILD $28,299,000,000.00
- ANET $6,613,147,000.00
- Revenue This Year
- GILD $6.54
- ANET $21.33
- Revenue Next Year
- GILD N/A
- ANET $18.31
- P/E Ratio
- GILD $937.76
- ANET $52.38
- Revenue Growth
- GILD 3.31
- ANET 18.19
- 52 Week Low
- GILD $62.07
- ANET $56.65
- 52 Week High
- GILD $98.90
- ANET $116.94
- Technical
- Relative Strength Index (RSI)
- GILD 52.30
- ANET 55.68
- Support Level
- GILD $90.27
- ANET $107.68
- Resistance Level
- GILD $93.59
- ANET $116.94
- Average True Range (ATR)
- GILD 2.12
- ANET 4.04
- MACD
- GILD -0.21
- ANET 0.12
- Stochastic Oscillator
- GILD 50.91
- ANET 45.99
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.